[Equilin sulphate in the treatment of the menopausal syndrome (author's transl)].
0.25 sodium equilin sulphate and 0.625 mg Premarin were compared as to their effects in 12 postmenopausal syndrome. The initial daily dosage of 0.25 mg equilin had a stronger oestrongenic effect in the alleviation of vasomotor disturbances than subsequently-administered Premarin. No significant difference was found in effect on the vaginal epithelium or the endometrium or in the incidence of irregular bleeding. The number of women in whom withdrawal bleeding was reported was considerably reduced by lowering the dosage to 0.2 mg equilin sulphate. Consequently 0.2 to 0.3 mg equilin sulphate must be considered the optimum dosage.
D015068:17-Ketosteroids / Q000494:pharmacology*; D001341:Autonomic Nervous System / Q000187:drug effects; D002979:Climacteric / Q000187:drug effects; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004857:Equilin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D009422:Nervous System Diseases / Q000188:drug therapy; D010053:Ovary / Q000601:surgery; D011183:Postoperative Complications / Q000188:drug therapy; D012893:Sleep Wake Disorders / Q000188:drug therapy; D013577:Syndrome; D013997:Time Factors
D015068:17-Ketosteroids; D004857:Equilin